|Day Low/High||13.33 / 14.04|
|52 Wk Low/High||5.27 / 20.63|
In recent trading, shares of Proteostasis Therapeutics Inc have crossed above the average analyst 12-month target price of $17.00, changing hands for $19.41/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
Preliminary Biomarker Data Confirms PTI-428 Activity on CFTR mRNA in Human Subjects
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Here's the lowdown on the biotech companies that have come public this year.
Data Presented at 13th Annual ECFS Basic Science Conference on Novel Therapies Targeting Cystic Fibrosis
Company to Hold Investor Conference Call and Webcast to Outline Scientific and Corporate Updates on March 30, 2016
Offering will finance in part acquisition of Patheon Inc. and DPP Pharmaceuticals Business of DSM
Global CDMO company combines DSM Pharmaceutical Products and Patheon
JLL Partners (“JLL”), a leading middle-market private equity firm, and Royal DSM, the global Life Sciences and Materials Sciences company, today announced the creation of a new company, which will be a leading ...